Fresenius Kabi Launches Its Denosumab Biosimilars In Canada, Including The First And Only Ready-To-Use Pre-Filled Syringe Biosimilar For Oncology Indications
Toronto, ON /CNW/ - Fresenius Kabi Canada, a subsidiary of the global healthcare company Fresenius, announces the launch in Canada of Conexxence®¹ (denosumab 60 mg/mL) and Bomyntra®² (denosumab 120 mg/1.7 mL). With the arrival of these two new treatments, Fresenius Kabi continues to expand its biosimilar portfolio in Canada, reinforcing its leadership in bone health, rheumatology, and supportive oncology care.
Conexxence (denosumab) was approved by Health Canada in April 2026 for all indications of the reference product Prolia®³. Approved indications include the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, treatment-induced bone loss, and bone mass enhancement in patients at high risk of fracture.
Bomyntra (denosumab) was approved by Health Canada in April 2026 for all indications of the reference product Xgeva®⁴. Approved indications include the prevention of bone complications in patients with bone metastases from solid tumors, the prevention of bone complications in patients with multiple myeloma, and the treatment of adults and adolescents of skeletal maturity with unresectable giant cell bone tumors or for whom surgical resection is likely to result in serious morbidity.
These launches are part of the continued expansion of Fresenius Kabi Canada's biosimilars portfolio in several therapeutic areas and demonstrate the company's broader commitment to improving access to biologic treatments for Canadian patients.
“The launch of our denosumab biosimilars demonstrates our commitment to improving access to high-quality biologic therapies, while also contributing to increased healthcare system efficiency and better cost control,” said Niamh Furey, Senior Vice President, Biopharma Europe and Rest of World, Fresenius Kabi. “As the first and only biosimilar company to offer a ready-to-use pre-filled syringe presentation in Canada for denosumab oncology indications, we are providing a new treatment option designed to simplify administration for both patients and healthcare professionals.”
About Fresenius Kabi Biopharma Canada
Fresenius Kabi is a global healthcare company specializing in life-saving medicines and technologies. Through its growing portfolio of biosimilars, Fresenius Kabi is committed to improving access to biologic therapies in immunology, rheumatology, bone health, oncology, and specialty care. In Canada, Fresenius Kabi markets biosimilars including Idacio (adalimumab), Tyenne (tocilizumab), Otulfi (ustekinumab), Conexxence (denosumab), and Bomyntra (denosumab). Additional biosimilars are in development to further expand patient access to affordable biologic therapies.
About Conexxence
The active ingredient in Conexxence is denosumab. Denosumab is a monoclonal antibody that inhibits RANKL, thereby reducing bone resorption and increasing bone mass. Conexxence is administered by subcutaneous injection.
The Conexxence biosimilar development program included analytical, non-clinical and clinical studies confirming equivalent efficacy and comparable safety to Prolia³, including a Phase 1 pharmacokinetic and pharmacodynamic study in healthy volunteers and a Phase 3 study (LUMIADE-3)⁵.
Conexxence is approved in Canada⁶ and other major markets, including the United States⁷ and the European Union⁸, for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, as well as for bone loss associated with hormone suppression in cancer patients.
About Bomyntra
The active ingredient in Bomyntra is denosumab. Denosumab inhibits RANKL, thereby reducing bone destruction associated with malignant tumors. Bomyntra is administered by subcutaneous injection.
The development program for the biosimilar Bomyntra included analytical, non-clinical and clinical studies confirming equivalent efficacy and comparable safety to those of Prolia³, including a Phase 1 pharmacokinetic and pharmacodynamic study conducted in healthy volunteers and a Phase 3 study (LUMIADE-3)⁵.
Bomyntra is approved in Canada⁹ and other major markets, including the United States¹⁰ and the European Union¹¹, for the prevention of bone-related events in adults with advanced malignant bone tumors and for the treatment of giant cell bone tumors.
About Fresenius Kabi
Fresenius Kabi, an operating company of the Fresenius Group, is a global healthcare company that provides medicines, technologies, and integrated services to patients with serious or chronic diseases. With over 41,000 employees and a presence in more than 100 countries, the company offers a broad portfolio of products that promotes access to high-quality care in emergency medicine, surgery, oncology, critical care, and home healthcare, reaching 450 million patients annually.
Through its complementary business areas, Fresenius Kabi offers highly complex biopharmaceutical products for the treatment of cancer as well as autoimmune and endocrine diseases; leading solutions in enteral, parenteral and home clinical nutrition; cutting-edge medical technologies, including infusion pumps, cell and gene therapy devices, single-use products and world-renowned blood collection systems; as well as generic drugs and intravenous solutions that contribute to essential patient care worldwide.
For more information, visit www.fresenius-kabi.com .
About Fresenius
Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg vor der Höhe, Germany. In fiscal year 2025, Fresenius generated annual revenues of €22.6 billion. Fresenius currently employs more than 178,000 people. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios, as well as a stake in Fresenius Medical Care. With approximately 140 hospitals and numerous outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 27 million patients annually. Fresenius Kabi's portfolio reaches 450 million patients annually and includes highly complex biopharmaceuticals, clinical nutrition products, medical technologies, as well as generic drugs and intravenous solutions. Fresenius was founded in 1912 by Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over the company in 1952. She laid the foundations for a global company whose goal today is to improve the health of populations. Its principal shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.
For more information, visit the company's website: www.fresenius.com .
References
1 Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in certain countries.
2 Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in certain countries.
3 Prolia® is a registered trademark of Amgen Inc.
4 Xgeva® is a registered trademark of Amgen Inc.
5 ClinicalTrials.gov. Study to evaluate the efficacy, pharmacodynamics, safety, and immunogenicity of FKS518 in postmenopausal women with osteoporosis. Available at: https://clinicaltrials.gov/search?term=NCT04934072 [Last accessed October 2026].
6 Conexxence (denosumab), Health Canada product description. Available at: https://dhpp.hpfb-dgpsa.ca/dhpp/resource/107005 [Last accessed October 2026].
7 Conexxence (denosumab), US Drug Facts. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761398Orig1s000lbl.pdf [Last accessed October 2026].
8 Conexxence (denosumab), Summary of Product Characteristics of the European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/conexxence [Last accessed October 2026].
9 Bomyntra (denosumab), Health Canada product description. Available at: https://dhpp.hpfb-dgpsa.ca/dhpp/resource/107006 [Last accessed October 2026].
10 Bomyntra (denosumab), US Drug Facts. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761398Orig1s000lbl.pdf [Last accessed October 2026].
11 Bomyntra (denosumab), Summary of Product Characteristics of the European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/bomyntra [Last accessed October 2026].
Source: Fresenius Kabi Canada
Copyright 2026 PR Newswire. All Rights Reserved